查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961474

特發性肺纖維化市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Idiopathic Pulmonary Fibrosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球特發性肺纖維化市場預計將從 2025 年的 38.8 億美元成長到 2031 年的 57.3 億美元，複合年成長率為 6.71%。

特發性肺纖維化 (IPF) 的治療方法包括抗纖維化藥物和輔助性治療，旨在延緩肺部不可逆疤痕的形成並維持呼吸功能。這一成長主要受全球人口老化加劇、該疾病與老化密切相關以及高解析度成像技術進步（可實現早期精準診斷）等因素所驅動。根據肺纖維化基金會 2024 年的數據，肺纖維化和間質性肺病影響超過 25 萬美國人，每年新增病例約 5 萬例。

市場概覽
預測期 2027-2031
市場規模：2025年 38.8億美元
市場規模：2031年 57.3億美元
複合年成長率：2026-2031年 6.71%
成長最快的細分市場 Pirfenidone
最大的市場 北美洲

儘管存在這些積極因素，但市場擴張仍面臨許多障礙。其中包括長期抗纖維化治療的高成本，這在醫保報銷政策嚴格的地區，阻礙了患者的就醫。此外，支付方嚴格的核准標準往往使這一經濟障礙更加複雜，限制了這些延長生命的治療方法在已開發地區和新興地區的廣泛應用。

市場促進因素

特發性肺纖維化 (IPF) 發病率的上升是市場發展的主要驅動力，這需要更廣泛地提供治療方法並擴大患者支持基礎設施。診斷技術的進步使醫療專業人員能夠發現更多這種慢性進行性性肺部疾病的病例，從而增加了對長期管理策略的需求。這種日益加重的疾病負擔並非區域性問題，而是全球性的健康挑戰，推動了對有效治療方法的商業性需求。例如，加拿大肺纖維化基金會於 2024 年 9 月發布的新聞稿《希望在此呼吸》(Hope Breathes Here) 指出，目前約有 3 萬名加拿大人患有肺纖維化，凸顯了需要護理的患者群體規模龐大。

同時，先進抗纖維化療法的快速普及顯著提升了市場價值。這些藥物被定位為延緩疾病進展的標準療法，現有藥物的商業性成功推動了研發，從而形成了以療效和安全性為核心的競爭格局。對藥物介入的強勁需求也反映在財務業績上。根據勃林格殷格翰於2024年4月發布的2023會計年度年度報告，其以Ofev為首的纖維化治療產品組合的淨銷售額達到35億歐元。此外，對未來創新的投資持續吸引市場，例如Vicore Pharma在2024年進行的股份增發，籌集了約7.82億瑞典克朗，用於推進其主要候選藥物的臨床試驗。

市場挑戰

長期抗纖維化治療的高昂費用是限制全球特發性肺纖維化（IPF）市場成長的主要經濟障礙。雖然這些藥物能有效延緩疾病進展，但其高昂的價格往往超出病患和醫療體系的負擔能力。因此，保險公司和支付方經常設定嚴格的報銷標準，例如要求在核准前提供肺功能受損的證明。這會延遲治療的啟動，縮小合格的患者群體，最終降低收入潛力。

這種經濟負擔不僅阻礙了新患者的招募，也導致了較高的治療中斷率。面對高昂的自付費用，患者被迫優先購買生活必需品而非繼續治療，導致臨床療效下降和藥品銷售量減少。肺纖維化基金會在2024年指出，在新的費用上限實施之前，美國聯邦醫療保險受益人每年處方藥的自付費用上限約為8000美元，這凸顯了老年人（該疾病最易感人群）面臨的沉重經濟負擔。這些經濟壓力造成了一種限制性環境，阻礙了治療方法的廣泛應用，進而阻礙了整體市場的擴張。

市場趨勢

人工智慧 (AI) 與診斷影像技術的融合正在改變全球特發性肺纖維化市場，它以自動化的定量生物標記取代了主觀的人工評估，從而更準確地預測疾病進展。這些人工智慧工具分析電腦斷層掃描 (CT) 影像，測量肺部結構的變化，為臨床醫生提供可靠的數據，用於患者分層和臨床試驗中的個人化醫療。根據美國國立衛生研究院 (NIH) 於 2025 年 3 月發布的 ERS ​​2024 年大會亮點報告，人工智慧衍生的加權網狀評分 (WRVS) 展現出優於傳統檢測法的預後能力，其識別高死亡風險患者的風險比為 4.55。

此外，新一代機制特異性治療方法的出現標誌著抗纖維化治療從廣譜藥物轉向靶向特定病理通路（例如溶血磷脂酸訊號通路）的精準藥物的重大轉變。這一趨勢的驅動力在於迫切需要提高患者的依從性和治療效果，而這些藥物與Pirfenidone和尼達尼布等傳統療法相比，具有更高的安全性和更精準的定向。根據2025年7月發表在《胸科醫師》（Chest Physician）雜誌上的報導“Admirparant II期試驗結果為肺纖維化聯合治療帶來希望”，在接受60毫克劑量治療的特發性肺纖維化患者中，在研的LPA1拮抗劑admirparant使肺功能下降的相對風險降低了54%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球特發性肺纖維化市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類型（Pirfenidone、尼達尼布、其他）
    • 給藥途徑（腸外、口服、其他）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美特發性肺纖維化市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲特發性肺纖維化市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區特發性肺纖維化市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲特發性肺纖維化市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲特發性肺纖維化市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球特發性肺纖維化市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Cipla Limited
  • Shionogi & Co., Ltd
  • Bristol-Myers Squibb Company
  • United Therapeutics Corporation
  • FibroGen, Inc
  • Pliant Therapeutics, Inc
  • Galecto, Inc.
  • CSL Behring

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19233

The Global Idiopathic Pulmonary Fibrosis Market is projected to expand from USD 3.88 billion in 2025 to USD 5.73 billion by 2031, reflecting a compound annual growth rate of 6.71%. Therapeutics for Idiopathic Pulmonary Fibrosis (IPF) include antifibrotic drugs and adjunctive treatments aimed at slowing irreversible lung scarring and maintaining respiratory capacity. This growth is primarily driven by an aging global population, given the strong correlation between the disease and advanced age, as well as advancements in high-resolution imaging that allow for earlier and more precise diagnosis. Data from the Pulmonary Fibrosis Foundation in 2024 indicates that pulmonary fibrosis and interstitial lung diseases affect more than 250,000 Americans, with roughly 50,000 new diagnoses annually.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.88 Billion
Market Size 2031USD 5.73 Billion
CAGR 2026-20316.71%
Fastest Growing SegmentPirfenidone
Largest MarketNorth America

Despite these positive factors, market expansion faces a major obstacle in the form of the high cost of long-term antifibrotic treatments, which hinders patient access in healthcare systems with strict reimbursement policies. This financial hurdle, often compounded by stringent payer approval criteria, restricts the broad utilization of these life-extending therapies across both developed and emerging regions.

Market Driver

The rising prevalence of Idiopathic Pulmonary Fibrosis (IPF) acts as a key determinant of market progress, requiring a corresponding increase in therapeutic availability and patient support infrastructures. Improvements in diagnostic capabilities enable healthcare providers to detect more instances of this chronic, progressive lung condition, thereby escalating the demand for long-term management strategies. This increasing disease burden is a global health issue rather than a regional one, fueling the commercial need for effective treatments; for instance, the Canadian Pulmonary Fibrosis Foundation's 'Hope Breathes Here Press Release' in September 2024 noted that approximately 30,000 Canadians are currently living with pulmonary fibrosis, underscoring the large patient population needing care.

Concurrently, the rapid uptake of advanced antifibrotic therapies significantly boosts market value, as these medications remain the standard of care for retarding disease progression. The commercial viability of existing agents stimulates ongoing research and development, fostering a competitive landscape focused on efficacy and safety. The strong demand for pharmaceutical interventions is reflected in financial results; Boehringer Ingelheim's April 2024 'Annual Report 2023' reported net sales of 3.5 billion EUR for their fibrosis portfolio, led by Ofev. Furthermore, the market continues to attract investment for future innovations, as demonstrated by Vicore Pharma, which raised approximately 782 million SEK in a 2024 rights issue to progress its lead candidate through clinical trials.

Market Challenge

The exorbitant cost associated with long-term antifibrotic therapy represents a major economic hurdle slowing the growth of the Global Idiopathic Pulmonary Fibrosis (IPF) Market. Although these medications effectively retard disease progression, their high prices often surpass the financial capacity of both patients and healthcare systems. As a result, insurance providers and payers frequently enforce rigorous reimbursement standards, such as necessitating proof of lung function decline prior to approval, which delays the start of treatment and shrinks the eligible patient pool, ultimately lowering revenue potential.

This financial toxicity not only hinders new patient enrollment but also leads to high rates of treatment abandonment. Patients confronted with significant out-of-pocket costs are often compelled to prioritize essential living expenses over medication adherence, resulting in poorer clinical outcomes and decreased drug sales volume. Highlighting this burden, the Pulmonary Fibrosis Foundation noted in 2024 that Medicare beneficiaries in the United States faced an annual out-of-pocket spending cap of roughly $8,000 for prescription drugs before new limits were enacted, demonstrating the severe economic strain on the elderly population most susceptible to the disease. These economic pressures create a restrictive atmosphere that suppresses the widespread uptake of therapeutics, thereby impeding overall market expansion.

Market Trends

The integration of Artificial Intelligence into diagnostic imaging is transforming the Global Idiopathic Pulmonary Fibrosis Market by substituting subjective manual evaluations with automated, quantitative biomarkers that more accurately predict disease progression. These AI-powered tools examine computed tomography scans to measure variations in lung structure, equipping clinicians with reliable data for patient stratification in clinical trials and personalized care. According to a March 2025 report by the National Institutes of Health on highlights from the 'ERS Congress 2024', the AI-derived Weighted Reticulovascular Score (WRVS) showed superior prognostic ability over traditional densitometry, identifying patients with a high mortality risk through a hazard ratio of 4.55.

Additionally, the rise of Next-Generation Mechanism-Specific Therapies marks a critical transition from broad-spectrum antifibrotics to precision agents that target specific pathogenic pathways, such as lysophosphatidic acid signaling. This trend is motivated by the critical need to enhance patient adherence and results via drugs that provide improved safety profiles and targeted efficacy compared to legacy treatments like pirfenidone and nintedanib. As reported by Chest Physician in July 2025 regarding the article 'Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis', the investigational LPA1 antagonist admilparant resulted in a 54% relative risk reduction in lung function decline among idiopathic pulmonary fibrosis patients treated with the 60 mg dose.

Key Market Players

  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Cipla Limited
  • Shionogi & Co., Ltd
  • Bristol-Myers Squibb Company
  • United Therapeutics Corporation
  • FibroGen, Inc
  • Pliant Therapeutics, Inc
  • Galecto, Inc.
  • CSL Behring

Report Scope

In this report, the Global Idiopathic Pulmonary Fibrosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Idiopathic Pulmonary Fibrosis Market, By Drug Type

  • Pirfenidone
  • Nintedanib
  • others

Idiopathic Pulmonary Fibrosis Market, By Route of Administration

  • Parenteral
  • Oral
  • Others

Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Idiopathic Pulmonary Fibrosis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Idiopathic Pulmonary Fibrosis Market.

Available Customizations:

Global Idiopathic Pulmonary Fibrosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Idiopathic Pulmonary Fibrosis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Pirfenidone, Nintedanib, others)
    • 5.2.2. By Route of Administration (Parenteral, Oral, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Idiopathic Pulmonary Fibrosis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Idiopathic Pulmonary Fibrosis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Idiopathic Pulmonary Fibrosis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Idiopathic Pulmonary Fibrosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Boehringer Ingelheim International GmbH
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. Cipla Limited
  • 15.4. Shionogi & Co., Ltd
  • 15.5. Bristol-Myers Squibb Company
  • 15.6. United Therapeutics Corporation
  • 15.7. FibroGen, Inc
  • 15.8. Pliant Therapeutics, Inc
  • 15.9. Galecto, Inc.
  • 15.10. CSL Behring

16. Strategic Recommendations

17. About Us & Disclaimer